Advertisement


Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers

ASCO 2026

Advertisement

Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007). 

 



Related Videos

Leukemia

Daniel A. Ermann, MD, on Two Agents in Treatment-Naive Patients With CLL: Real-World Treatment and Survival Outcomes

Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-line treatment for patients with chronic lymphocytic leukemia (CLL) based on overall survival and time to next treatment (Abstract 7045). 

Lung Cancer

Jonathan W. Goldman, MD, on RET Fusion–Positive NSCLC: Adjuvant Selpercatinib

Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).

Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View

Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abstract LBA5).

Lymphoma
Leukemia

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012). 

Leukemia

Daniel A. Ermann, MD, on First-Line Therapy for CLL: Real-World Outcomes Among Medicare Beneficiaries

Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047). 

To learn more about this data, read a related article in Oncology and Therapy.

Advertisement

Advertisement




Advertisement